Rocket Pharmaceuticals officer plans $11.3K sale
The proposed sale follows compensation-related restricted-stock vesting, and an amount is included to cover a tax obligation tied to the vested award distribution.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rocket Pharmaceuticals, Inc. (RCKT) lists Officer Sarbani Chaudhuri's proposed sale of 4,872 common shares, with an aggregate market value of $11,335.20 and an approximate sale date of November 9, 2026. The shares were acquired as compensation through restricted stock vesting on November 5, 2026. The notice states that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. It also lists a sale of 4,701 shares on August 11, 2026, for gross proceeds of $16,450.68.
Key Figures
Key Terms
Restricted Stock Vesting financial
equity award distribution financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.